Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders.

@article{Sather2011DevelopmentOB,
  title={Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders.},
  author={Blythe D. Sather and Byoung Y. Ryu and Brigid V Stirling and Mikhail Garibov and Hannah M M Kerns and St{\'e}phanie Humblet-Baron and Alexander Astrakhan and David J Rawlings},
  journal={Molecular therapy : the journal of the American Society of Gene Therapy},
  year={2011},
  volume={19 3},
  pages={
          515-25
        }
}
Sustained, targeted, high-level transgene expression in primary B lymphocytes may be useful for gene therapy in B cell disorders. We developed several candidate B-lineage predominant self-inactivating lentiviral vectors (LV) containing alternative enhancer/promoter elements including: the immunoglobulin β (Igβ) (B29) promoter combined with the immunoglobulin µ enhancer (EµB29); and the endogenous BTK promoter with or without Eµ (EµBtkp or Btkp). LV-driven enhanced green fluorescent protein… CONTINUE READING